Skip to main content
Erschienen in: Clinical and Experimental Nephrology 3/2019

08.09.2018 | Original article

Biological variation of procalcitonin levels in hemodialysis patients

verfasst von: Shun Kubo, Masaki Iwasaki, Mari Horie, Ai Matsukane, Toshihide Hayashi, Yuri Tanaka, Hiroki Hase, Nobuhiko Joki

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

There is no obvious evidence regarding biological variation of procalcitonin (PCT) levels in hemodialysis (HD) patients without infections. The aim of this study was to determine the within- and between-person biological variation of PCT levels in HD patients without infections.

Methods

A multicenter, prospective, cohort study enrolled 123 HD patients without any signs of infectious disease. Baseline PCT levels were determined pre- and post-HD, and then repeated pre-HD PCT measurements were performed at 2, 4, 8, 12, 16, 20, and 24 weeks after baseline blood-sampling, regardless of the presence or absence of infectious disease. Analytical variation (CVa), the within-person biological variation (CVi), between-person biological variation (CVb), individual index (II), and the reference change value (RCV) were calculated.

Results

The mean age was 62.4 years, 76.4% were male, and 32.5% had diabetes. The mean duration of HD was 87 months. The median value for baseline pre-HD PCT was 0.23 ng/mL, which is much higher than the reference level for healthy individuals. PCT levels decreased of 46.6% after a single HD session. CVi was 24.9%, CVb was 54.2%, II was 0.46, and RCV was calculated as 96.4% with 99% probability.

Conclusions

The PCT level was significantly higher in stable HD patients without manifest bacterial infection. CVb was more variable than CVi in HD patients, which indicates that relative change is more important than absolute PCT levels for diagnosing bacterial infection, and doubling or more of the baseline PCT level may imply the presence of a bacterial infection in HD patients.
Literatur
1.
Zurück zum Zitat Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl. 1993;41:143-8. Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl. 1993;41:143-8.
2.
Zurück zum Zitat Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial. 2013;17:298–304.CrossRefPubMed Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial. 2013;17:298–304.CrossRefPubMed
3.
Zurück zum Zitat Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in japan (as of 31 december 2010). Ther Apher Dial. 2012;16:483–521.CrossRefPubMed Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in japan (as of 31 december 2010). Ther Apher Dial. 2012;16:483–521.CrossRefPubMed
4.
Zurück zum Zitat Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643–52.CrossRefPubMed Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643–52.CrossRefPubMed
5.
Zurück zum Zitat Iwasaki M, Joki N, Tanaka Y, Ikeda N, Hayashi T, Kubo S, et al. Efficacy of n-terminal pro-brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients. Nephrology (Carlton). 2013;18:497–504.CrossRef Iwasaki M, Joki N, Tanaka Y, Ikeda N, Hayashi T, Kubo S, et al. Efficacy of n-terminal pro-brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients. Nephrology (Carlton). 2013;18:497–504.CrossRef
6.
Zurück zum Zitat Iwasaki M, Yamazaki K, Ikeda N, Tanaka Y, Hayashi T, Kubo S, et al. Point of care assessment of cardiac troponin t level in ckd patients with chest symptom. Renal Fail. 2017;39:166–172CrossRef Iwasaki M, Yamazaki K, Ikeda N, Tanaka Y, Hayashi T, Kubo S, et al. Point of care assessment of cardiac troponin t level in ckd patients with chest symptom. Renal Fail. 2017;39:166–172CrossRef
7.
Zurück zum Zitat Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515–8.CrossRefPubMed Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515–8.CrossRefPubMed
8.
Zurück zum Zitat Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941–52.CrossRefPubMed Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941–52.CrossRefPubMed
9.
Zurück zum Zitat Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30:1112–7.CrossRefPubMed Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30:1112–7.CrossRefPubMed
10.
Zurück zum Zitat Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother. 2012;67:2560–9.CrossRefPubMed Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother. 2012;67:2560–9.CrossRefPubMed
11.
Zurück zum Zitat Koji Ichihara TT, Takahashi S, Matsukawa M, Yanase M, Kitamura H, Masumori N. Serum procalcitonin level in chronic hemodialytic patients with no evidence of bacterial infection. Renal Replace Ther. 2016;2:9.CrossRef Koji Ichihara TT, Takahashi S, Matsukawa M, Yanase M, Kitamura H, Masumori N. Serum procalcitonin level in chronic hemodialytic patients with no evidence of bacterial infection. Renal Replace Ther. 2016;2:9.CrossRef
12.
Zurück zum Zitat Trimarchi H, Dicugno M, Muryan A, Lombi F, Iturbe L, Rana MS, et al. Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires). 2013;73:411–6. Trimarchi H, Dicugno M, Muryan A, Lombi F, Iturbe L, Rana MS, et al. Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires). 2013;73:411–6.
13.
Zurück zum Zitat Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol. 2001;18:79–87.CrossRefPubMed Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol. 2001;18:79–87.CrossRefPubMed
14.
Zurück zum Zitat Quiroga B, Villaverde M, Vega A, Abad S, Reque J, Lopez-Gomez JM. Procalcitonin as an early predictor of acute infection in hemodialysis patients. Nefrologia. 2014;34:341–6.PubMed Quiroga B, Villaverde M, Vega A, Abad S, Reque J, Lopez-Gomez JM. Procalcitonin as an early predictor of acute infection in hemodialysis patients. Nefrologia. 2014;34:341–6.PubMed
15.
Zurück zum Zitat Mori K, Noguchi M, Sumino Y, Sato F, Mimata H. Use of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. ISRN Urol. 2012;2012:431859.PubMedPubMedCentral Mori K, Noguchi M, Sumino Y, Sato F, Mimata H. Use of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. ISRN Urol. 2012;2012:431859.PubMedPubMedCentral
16.
Zurück zum Zitat Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume kt/v: an analysis of error. J Am Soc Nephrol. 1993;4:1205–13.PubMed Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume kt/v: an analysis of error. J Am Soc Nephrol. 1993;4:1205–13.PubMed
17.
Zurück zum Zitat Braga F, Panteghini M. Generation of data on within-subject biological variation in laboratory medicine: an update. Crit Rev Clin Lab Sci. 2016;53:313–25.CrossRefPubMed Braga F, Panteghini M. Generation of data on within-subject biological variation in laboratory medicine: an update. Crit Rev Clin Lab Sci. 2016;53:313–25.CrossRefPubMed
18.
Zurück zum Zitat Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers c-reactive protein, white blood cell count, and neutrophil percentage. Int Urol Nephrol. 2017;49:2205–2216CrossRefPubMed Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers c-reactive protein, white blood cell count, and neutrophil percentage. Int Urol Nephrol. 2017;49:2205–2216CrossRefPubMed
19.
Zurück zum Zitat Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin. Diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol. 2014;46:461–8.CrossRefPubMed Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin. Diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol. 2014;46:461–8.CrossRefPubMed
20.
Zurück zum Zitat Dahaba AA, Rehak PH, List WF. Procalcitonin and c-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29:579–83.CrossRefPubMed Dahaba AA, Rehak PH, List WF. Procalcitonin and c-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29:579–83.CrossRefPubMed
21.
Zurück zum Zitat Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002;15:297–301.PubMed Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002;15:297–301.PubMed
22.
Zurück zum Zitat Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–911.CrossRefPubMed Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–911.CrossRefPubMed
23.
Zurück zum Zitat Tanaka Y, Joki N, Hase H, Iwasaki M, Ikeda M, Ando R, et al. Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond). 2012;9:17.CrossRef Tanaka Y, Joki N, Hase H, Iwasaki M, Ikeda M, Ando R, et al. Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond). 2012;9:17.CrossRef
24.
Zurück zum Zitat Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61:180–6.CrossRefPubMed Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61:180–6.CrossRefPubMed
25.
Zurück zum Zitat Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, Kribben A. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001;16:975–9.CrossRefPubMed Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, Kribben A. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001;16:975–9.CrossRefPubMed
26.
Zurück zum Zitat Montagnana M, Lippi G, Tessitore N, Salvagno GL, Danese E, Targher G, et al. Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scand J Clin Lab Invest. 2009;69:703–7.CrossRefPubMed Montagnana M, Lippi G, Tessitore N, Salvagno GL, Danese E, Targher G, et al. Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scand J Clin Lab Invest. 2009;69:703–7.CrossRefPubMed
27.
Zurück zum Zitat Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, et al. N-terminal pro-b-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015;10:620–9.CrossRefPubMedPubMedCentral Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, et al. N-terminal pro-b-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015;10:620–9.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin t and cardiac troponin i in hemodialysis patients and healthy controls. Clin Chem. 2014;60:838–47.CrossRefPubMed Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin t and cardiac troponin i in hemodialysis patients and healthy controls. Clin Chem. 2014;60:838–47.CrossRefPubMed
29.
Zurück zum Zitat Aakre KM, Roraas T, Petersen PH, Svarstad E, Saele K, Sandberg S. Week-to-week biological variation in the n-terminal prohormone of brain natriuretic peptide in hemodialysis patients and healthy individuals. Clin Chem. 2013;59:1813–4.CrossRefPubMed Aakre KM, Roraas T, Petersen PH, Svarstad E, Saele K, Sandberg S. Week-to-week biological variation in the n-terminal prohormone of brain natriuretic peptide in hemodialysis patients and healthy individuals. Clin Chem. 2013;59:1813–4.CrossRefPubMed
Metadaten
Titel
Biological variation of procalcitonin levels in hemodialysis patients
verfasst von
Shun Kubo
Masaki Iwasaki
Mari Horie
Ai Matsukane
Toshihide Hayashi
Yuri Tanaka
Hiroki Hase
Nobuhiko Joki
Publikationsdatum
08.09.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 3/2019
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1639-2

Weitere Artikel der Ausgabe 3/2019

Clinical and Experimental Nephrology 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.